This study evaluates the performance of a blood test for detecting biomarkers in metastatic
breast cancer patients at one clinic against standard testing.
The primary objective of this pilot study is to detect the expression of FGFR1 and AR on
circulating tumor cells (CTCs) isolated from the peripheral blood of metastatic breast
cancer (MBC) patients using the OncoCEE™ platform. No procedures will be associated with
this study, as these mutations will be evaluated from the leftover blood that has already
been sent for standard of care ER and HER2 using the same platform. Results from this
testing will be correlated with results obtained from standard testing to calculate the rate
of concordance between tests.
- Current patient at participating clinic
- Metastatic breast cancer diagnosis
- 18 years of age or older